Display options
Share it on

Pharmaceutics. 2021 Jul 28;13(8). doi: 10.3390/pharmaceutics13081163.

Biobased Ionic Liquids as Multitalented Materials in Lipidic Drug Implants.

Pharmaceutics

Ana Júlio, Anaisa Sultane, Ana Silveira Viana, Joana Portugal Mota, Tânia Santos de Almeida

Affiliations

  1. CBIOS-Universidade Lusófona's Research Center for Biosciences & Health Technologies, Campo Grande 376, 1749-024 Lisboa, Portugal.
  2. Department of Biomedical Sciences, University of Alcalá, Ctra. Madrid-Barcelona Km. 33.600, Alcalá de Henares, 28871 Madrid, Spain.
  3. Centro de Química Estrutural, Faculdade de Ciências, Universidade de Lisboa, Campo Grande, 1749-016 Lisbon, Portugal.

PMID: 34452124 PMCID: PMC8401770 DOI: 10.3390/pharmaceutics13081163

Abstract

Lipidic implants are valuable controlled delivery systems that present good biocompatibility and are useful for long-lasting therapies. However, these promising systems can present inflexible drug release profiles that limit their performance. Thus, finding new materials to overcome this drawback is crucial. Herein, lipidic implants containing caffeine and poorly soluble salicylic acid and rutin were developed. The inclusion of Gelucire

Keywords: caffeine; improved performance; ionic liquids; lipidic implants; rutin; salicylic acid

References

  1. J Cosmet Dermatol. 2008 Mar;7(1):23-9 - PubMed
  2. Int J Pharm. 2013 Jan 30;441(1-2):620-7 - PubMed
  3. Expert Opin Drug Deliv. 2008 Mar;5(3):291-307 - PubMed
  4. Pharmaceutics. 2019 Feb 22;11(2): - PubMed
  5. Ther Deliv. 2017 Jun;8(6):461-473 - PubMed
  6. Drug Discov Today. 2020 May;25(5):901-908 - PubMed
  7. Drug Dev Ind Pharm. 2017 Nov;43(11):1858-1865 - PubMed
  8. Int J Artif Organs. 2011 Feb;34(2):238-42 - PubMed
  9. Psychopharmacology (Berl). 2016 May;233(10):1963-79 - PubMed
  10. Saudi Pharm J. 2017 Feb;25(2):149-164 - PubMed
  11. Nanomaterials (Basel). 2019 Aug 10;9(8): - PubMed
  12. PLoS One. 2015 Nov 25;10(11):e0143447 - PubMed
  13. ACS Appl Mater Interfaces. 2020 Feb 5;12(5):5169-5176 - PubMed
  14. Int J Mol Sci. 2020 Nov 05;21(21): - PubMed
  15. Eur J Pharm Biopharm. 2011 Aug;78(3):394-400 - PubMed
  16. ChemMedChem. 2021 Apr 27;: - PubMed
  17. Chemosphere. 2014 Jun;104:51-6 - PubMed
  18. Phys Chem Chem Phys. 2015 Jul 28;17(28):18238-61 - PubMed
  19. Annu Rev Chem Biomol Eng. 2014;5:527-46 - PubMed
  20. Phys Chem Chem Phys. 2014 Feb 21;16(7):3027-35 - PubMed
  21. Pharmaceutics. 2021 May 12;13(5): - PubMed
  22. Int J Pharm. 2006 May 18;314(2):145-52 - PubMed
  23. Expert Opin Investig Drugs. 2013 Aug;22(8):1063-79 - PubMed
  24. ChemMedChem. 2011 Jun 6;6(6):975-85 - PubMed
  25. Int J Pharm. 2009 Aug 13;378(1-2):152-8 - PubMed
  26. J Cosmet Dermatol. 2007 Jun;6(2):102-7 - PubMed
  27. Expert Opin Drug Deliv. 2005 Nov;2(6):1039-58 - PubMed
  28. Int J Pharm. 2006 May 18;314(2):137-44 - PubMed
  29. Eur J Pharm Sci. 2011 May 18;43(1-2):78-83 - PubMed
  30. Int J Pharm. 2011 Feb 14;404(1-2):27-35 - PubMed
  31. J Phys Chem B. 2009 Jan 15;113(2):465-73 - PubMed
  32. Macromol Rapid Commun. 2015 Aug;36(16):1498-504 - PubMed
  33. Biomolecules. 2020 Feb 04;10(2): - PubMed
  34. Pharmaceutics. 2018 Dec 19;10(4): - PubMed
  35. CNS Neurosci Ther. 2017 Apr;23(4):272-290 - PubMed
  36. J Control Release. 2007 Jun 4;119(2):163-72 - PubMed
  37. Skin Pharmacol Physiol. 2013;26(1):8-14 - PubMed
  38. Soft Matter. 2016 Nov 28;12(47):9501-9508 - PubMed
  39. Int J Mol Sci. 2021 Apr 21;22(9): - PubMed
  40. Expert Opin Drug Deliv. 2013 Oct;10(10):1367-81 - PubMed

Publication Types

Grant support